Literature DB >> 9540014

The relationship of menstrual irregularity to type 2 diabetes in Pima Indian women.

J Roumain1, M A Charles, M P de Courten, R L Hanson, T D Brodie, D J Pettitt, W C Knowler.   

Abstract

OBJECTIVE: Menstrual irregularity is associated with hyperinsulinemia and hyperandrogenemia in nondiabetic Pima Indian women of child-bearing age. In this population-based study, we determined the relationship of menstrual irregularity to type 2 diabetes in Pima Indian women. RESEARCH DESIGN AND METHODS: Participants for this cross-sectional analysis were 695 nonpregnant Pima Indian women, aged 18-44 years, involved in an ongoing epidemiologic study of diabetes among residents of the Gila River Indian Community of Arizona. Clinical data were collected by questionnaire and an examination that included a 75-g oral glucose tolerance test; diabetes was diagnosed by World Health Organization criteria. Menstrual irregularity was defined as an interval of 3 months or more between menses, when not pregnant, since age 18 years.
RESULTS: History of menstrual irregularity was significantly associated with a high prevalence of diabetes (37 vs. 13%; odds ratio = 4.2, 95% CI = 1.6-10.8) in the least obese women (BMI < 30 kg/m2), adjusted for the effects of age and overall obesity. This association was, in part, because of greater central obesity in women with irregular menses. In more obese women, there was little association with menstrual irregularity, and diabetes was frequent regardless of menstrual history.
CONCLUSIONS: Prevalence of type 2 diabetes is higher among Pima indian women with a history of menstrual irregularity. The difference is most pronounced among the least obese group of women. This association may be because of insulin resistance and hyperinsulinemia, which predict type 2 diabetes, also causing hyperandrogenism and menstrual irregularity. The findings reinforce the need to evaluate women with menstrual irregularity for hyperglycemia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9540014     DOI: 10.2337/diacare.21.3.346

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  7 in total

1.  Diabetes, medical comorbidities and couple fecundity.

Authors:  Michael L Eisenberg; Rajeshwari Sundaram; José Maisog; Germaine M Buck Louis
Journal:  Hum Reprod       Date:  2016-09-02       Impact factor: 6.918

2.  The severity of menstrual dysfunction as a predictor of insulin resistance in PCOS.

Authors:  Meredith Brower; Kathleen Brennan; Marita Pall; Ricardo Azziz
Journal:  J Clin Endocrinol Metab       Date:  2013-10-03       Impact factor: 5.958

Review 3.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

4.  Long menstrual cycle is associated with type 2 diabetes mellitus in korean women.

Authors:  Unjin Shim; Jee-Young Oh; Hye Jin Lee; Young Sun Hong; Yeon-Ah Sung
Journal:  Diabetes Metab J       Date:  2011-08-31       Impact factor: 5.376

5.  Low fertility and the risk of type 2 diabetes in women.

Authors:  Clara C Elbers; N Charlotte Onland-Moret; Marinus J C Eijkemans; Cisca Wijmenga; Diederick E Grobbee; Yvonne T van der Schouw
Journal:  Hum Reprod       Date:  2011-10-16       Impact factor: 6.918

6.  Menstrual and reproductive factors and type 2 diabetes risk: The Japan Public Health Center-based Prospective Study.

Authors:  Akiko Nanri; Tetsuya Mizoue; Mitsuhiko Noda; Atsushi Goto; Norie Sawada; Shoichiro Tsugane
Journal:  J Diabetes Investig       Date:  2018-06-05       Impact factor: 4.232

7.  Effects of hormone replacement therapy on glucose and lipid metabolism in peri- and postmenopausal women with a history of menstrual disorders.

Authors:  Saisai Li; Linjuan Ma; Ling Xu; Jianhong Zhou; Yang Song; Jiehong Zheng; Yuqun Cai; Hong Xu; Peiqiong Chen; Wenxian Xu; Yizhou Huang; Tongyun Qi; Chunming Li; Ketan Chu; Yibing Lan
Journal:  BMC Endocr Disord       Date:  2021-06-15       Impact factor: 2.763

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.